摘要
目的 探讨高选择性β1受体阻滞剂对于慢性阻塞性肺疾病患者肺功能的影响。方法 2012年2月~2013年12月期间,在我院门诊及住院部收集慢性阻塞性肺疾病（COPD）病例60例,随机分入两组,其中对照组（30例）采用“吸入性糖皮质激素（ICS）＋β2兴奋剂”治疗,而治疗组（30例）在此基础上再联合高选择性β1受体阻滞剂治疗,比较其对患者肺功能的影响。结果 治疗后,治疗组SGRQ评分的症状部分、活动部分、影响部分及总分,均明显低于对照组,差异有统计学意义（P〈0.05）;并且,在LVEF、FEV1、FEV1/FVC方面,治疗后治疗组改善率也明显优于对照组,差异有统计学意义（P〈0.05）。结论 高选择性β1受体阻滞剂对于COPD患者肺功能有着积极影响,并且安全可靠,值得临床进一步推广应用。
Objective To explore the influence of highly selective β-blocker on pulmonary function of patients with chronic obstructive pulmonary disease. Methods 60 patients with chronic obstructive pulmonary disease（COPD） who were admitted to clinic and inpatient department in our hospital from February, 2012 to December, 2013 were randomly allocated to the control group and the treatment group, with 30 in each. Patients in the control group were received ＂inhaled corticosteroids （ ICS ） ＋ beta 2 doping＂ treatment while patients in the treatment group were received this treatment combined with highly selective β-blocker. Its influences on pulmonary function of patients were compared. Results After treatment, scores of symptoms, activity, influence and total score in SGRQ scoring of the treatment group were all significantly lower than that of the control group. The differences were statistically significant（P 〈 0.05）. In addition, improvement rates in LVEF, FEV1, FEVI/FVC aspects of the treatment group aftr treatment were all significantly superior to those of the control group. The difference was statistically significant （P 〈 0.05）. Conclusion High selective β-blocker has a positive effect on pulmonary function of patients with COPD and it is safe and reliable which is worthy of further promotion and application in clinic.
出处
《中国医药科学》
2015年第14期186-188,共3页
China Medicine And Pharmacy
关键词
慢性阻塞性肺病
高选择性β1受体阻滞剂
肺功能
Chronic obstructive pulmonary disease
Highly selective β-blocker
Pulmonary function
